1.The clinical significance of C-reactive protein in patients with chronic renal failure.
Nam Ho KIM ; Soo Wan KIM ; Gi Sub YOO ; Jong Wook PARK ; Kwang Ki PARK ; Kyoung Hyup MOON ; Young Joon KANG
Korean Journal of Nephrology 1993;12(3):361-368
No abstract available.
C-Reactive Protein*
;
Humans
;
Kidney Failure, Chronic*
2.Bilateral Multiple Intracerebral Hemorrhagic Infarction after Cranioplasty in a Patient with Cerebral Infarction: Case Report.
Byung Sub KIM ; Do Sung YOO ; Pil Woo HUH ; Kyoung Suok CHO ; Sang Bok LEE
Korean Journal of Cerebrovascular Surgery 2010;12(3):136-140
Bilateral multiple intracranial hemorrhagic infarction after cranioplasty is an extremely rare complication. We present a case of a bilateral multiple intracranial hemorrhagic infarction following cranioplasty with an autologous bone graft. A 63-year-old woman had a previous decompressive craniectomy after a right middle cerebral artery infarction. The possible pathogenesis of the complication is discussed.
Decompressive Craniectomy
;
Female
;
Humans
;
Infarction
;
Infarction, Middle Cerebral Artery
;
Middle Aged
;
Reperfusion Injury
;
Transplants
3.Circulating Cancer Stem Cells Expressing EpCAM/CD90 in Hepatocellular Carcinoma: A Pilot Study for Predicting Tumor Recurrence after Living Donor Liver Transplantation
Hyeo Seong HWANG ; Jeong Eun YOO ; Dai Hoon HAN ; Jin Sub CHOI ; Jae Geun LEE ; Dong Jin JOO ; Myoung Soo KIM ; Soon Il KIM ; Gi Hong CHOI ; Young Nyun PARK
Gut and Liver 2022;16(3):443-455
Background/aims:
Circulating tumor cells (CTCs) with cancer stemness have been demonstrated to be a direct cause of tumor recurrence, and only few studies have reported the role of CTCs in liver transplantation (LT) for hepatocellular carcinoma (HCC).
Methods:
Epithelial cell adhesion molecule+ (EpCAM+), cluster of differentiation 90+ (CD90+) and EpCAM+/CD90+ CTCs were sorted via fluorescence-activated cell sorting, and transcripts level of EpCAM, K19 and CD90 in the peripheral blood were analyzed via real-time polymerase chain reaction preoperatively and on postoperative days 1 and 7 in 25 patients who underwent living donor liver transplantation (LDLT) for HCC. EpCAM protein was assessed in HCC tissue using immunohistochemical staining. The median follow-up duration was 40 months.
Results:
HCC after LDLT recurred in four out of 25 patients. Detection of EpCAM+ or CD90+ CTCs correlated well with their messenger RNA levels (p<0.05). EpCAM+ CTCs were readily detected in HCC tissue expressing EpCAM protein. The detection of EpCAM+ CTCs or EpCAM+/CD90+ CTCs before surgery and on postoperative day 1 was significantly associated with HCC recurrence after LT (all p<0.05). Pretransplant serum PIVKA-II >100 mAU/mL and postoperative day 1 EpCAM+/CD90+ CTCs were independent risk factors for HCC recurrence (hazard ratio, 14.64; 95% confidence interval, 1.08 to 198.20; p=0.043 and hazard ratio, 26.88; 95% confidence interval, 1.86 to 387.51; p=0.016, respectively).
Conclusions
EpCAM+/CD90+ CTCs can be used preoperatively and 1 day after LDLT as key biological markers in LT candidate selection and post-LDLT management.